Loading...
XHKG
9960
Market cap125mUSD
Jul 10, Last price  
0.98HKD
1D
3.16%
1Q
-14.04%
IPO
-88.05%
Name

Kindstar Globalgene Technology Inc

Chart & Performance

D1W1MN
XHKG:9960 chart
P/E
P/S
0.94
EPS
Div Yield, %
2.51%
Shrs. gr., 5y
49.86%
Rev. gr., 5y
0.93%
Revenues
934m
+0.65%
706,202,000832,791,000891,391,000930,673,0001,386,591,000967,260,000927,568,000933,565,000
Net income
-59m
L+7.61%
-52,674,000-169,788,000-974,020,000-1,454,430,00075,457,00041,286,000-54,588,000-58,742,000
CFO
91m
P
53,895,00099,448,00073,462,00068,028,00021,407,000-14,780,000-44,119,00091,174,000
Dividend
Jun 09, 20250.0238 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.
IPO date
Jul 16, 2021
Employees
3,214
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT